All Releases
 |
VIA Pharmaceuticals Licenses Drug Candidates from Roche to Expand Cardiovascular Pipeline to Include Metabolic Disease
Dec 23, 2008
|
10.7 KB |
|
| |
SAN FRANCISCO, Dec 23, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc.
(Nasdaq: VIAP), a biotechnology company focused on the development of
compounds for the treatment of cardiovascular disease, today announced
exclusive, worldwide licensing agreements with Roche (SWX: ROG) for two sets
of compounds. The first ...
|
|
VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
Nov 9, 2008
|
17.2 KB |
|
| |
NEW ORLEANS and SAN FRANCISCO, Nov 09, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today the results of two Phase 2 studies of its lead drug, VIA-2291. In each Phase 2 study, VIA...
|
|
VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
Nov 6, 2008
|
7.1 KB |
|
| |
SAN FRANCISCO, Nov 06, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it will hold a conference call and webcast to discuss results of the VIA-2291 Phase 2 acute coronary...
|
|
VIA Pharmaceuticals Announces Upcoming Investor Conference Presentations
Nov 4, 2008
|
6.7 KB |
|
| |
SAN FRANCISCO, Nov 04, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that VIA management will present at three upcoming investor conferences.
The presentation detai...
|
|
VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
Sep 24, 2008
|
10.3 KB |
|
| |
SAN FRANCISCO, Sept 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it has completed the last patient visit in its Phase 2 acute coronary syndrome (ACS) study, includi...
|
|
VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
Sep 15, 2008
|
9.9 KB |
|
| |
SAN FRANCISCO, Sept 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that two abstracts on the company's Phase 2 trials of VIA-2291 in patients with acute coronary syndrome ...
|
|
VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16
Sep 9, 2008
|
10.8 KB |
|
| |
SAN FRANCISCO, Sept 09, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it will host a science briefing on Tuesday, September 16, 2008 at 12:00pm Eastern Time in New York ...
|
|
VIA Pharmaceuticals to Present at Merriman Curhan Ford's Investor Summit 2008
Sep 9, 2008
|
7.2 KB |
|
| |
SAN FRANCISCO, Sept 09, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that James G. Stewart, senior vice president and chief financial officer, will present a company update at Mer...
|
|
VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
Aug 12, 2008
|
7.2 KB |
|
| |
SAN FRANCISCO, Aug 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that James G. Stewart, senior vice president and chief financial officer of VIA, will present a company u...
|
|
VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
Aug 1, 2008
|
6.8 KB |
|
| |
SAN FRANCISCO, Aug 01, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that Rebecca A. Taub, MD, VIA's senior vice president of research and development, will present at the 13...
|
|
VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial
Jul 10, 2008
|
11.3 KB |
|
| |
SAN FRANCISCO, July 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it has completed the last patient visit in its carotid endarterectomy (CEA) study. The excised caro...
|
|
VIA Pharmaceuticals Set to Join Russell Microcap Index
Jun 27, 2008
|
10.7 KB |
|
| |
SAN FRANCISCO, June 27, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, will join the Russell Microcap Index when Russell Investments reconstitutes its family of U.S. indexes on June 27 after ...
|
|
VIA Pharmaceuticals to Present at Seventh Annual Needham & Company Biotechnology and Medical Technology Conference
Jun 3, 2008
|
6.7 KB |
|
| |
SAN FRANCISCO, June 3, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that Lawrence K. Cohen, PhD, president and chief executive officer of VIA, and James G. Stewart, senior vice pr...
|
|
VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
May 15, 2008
|
11.2 KB |
|
| |
SAN FRANCISCO, May 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it has completed patient enrollment in its acute coronary syndrome (ACS) study. The ACS study is one...
|
|
VIA Pharmaceuticals to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
May 8, 2008
|
7.0 KB |
|
| |
SAN FRANCISCO, May 8, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that James G. Stewart, senior vice president and chief financial officer, will present a company update at the R...
|
|
VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
Apr 4, 2008
|
10.5 KB |
|
| |
SAN FRANCISCO, April 4, 2008, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that the independent Data Safety Monitoring Board (DSMB) for its VIA-2291 Phase 2 clinical trial program...
|
|
VIA Pharmaceuticals Complies With NASDAQ Rule
Mar 28, 2008
|
9.2 KB |
|
| |
SAN FRANCISCO, March 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today, in compliance with NASDAQ Marketplace Rule 4350(b)(1)(B), that the independent audit report included i...
|
|
VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
Mar 20, 2008
|
11.7 KB |
|
| |
SAN FRANCISCO, March 20, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it has completed patient enrollment in its carotid endarterectomy (CEA) study, the first of three Phase ...
|
|
VIA Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
Mar 11, 2008
|
6.7 KB |
|
| |
SAN FRANCISCO, March 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that Lawrence Cohen PhD, chief executive officer, and James G. Stewart, senior vice president and chief finan...
|
|
VIA Pharmaceuticals to Present at Susquehanna and Rodman & Renshaw Conferences on March 4, 2008
Feb 26, 2008
|
6.8 KB |
|
| |
SAN FRANCISCO, Feb 26, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that James G. Stewart, senior vice president, chief financial officer of VIA, will present a company upda...
|
|
|
